company background image
A086890 logo

ISU Abxis KOSDAQ:A086890 Stock Report

Last Price

₩5.93k

Market Cap

₩212.9b

7D

-5.6%

1Y

-1.8%

Updated

01 Nov, 2024

Data

Company Financials +

ISU Abxis Co., Ltd.

KOSDAQ:A086890 Stock Report

Market Cap: ₩212.9b

A086890 Stock Overview

A biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide.

A086890 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ISU Abxis Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ISU Abxis
Historical stock prices
Current Share Price₩5,930.00
52 Week High₩8,000.00
52 Week Low₩5,250.00
Beta0.72
11 Month Change-9.47%
3 Month Change-9.47%
1 Year Change-1.82%
33 Year Change-50.58%
5 Year Change-18.21%
Change since IPO-35.54%

Recent News & Updates

ISU Abxis Co., Ltd.'s (KOSDAQ:086890) Intrinsic Value Is Potentially 84% Above Its Share Price

Aug 07
ISU Abxis Co., Ltd.'s (KOSDAQ:086890) Intrinsic Value Is Potentially 84% Above Its Share Price

ISU Abxis (KOSDAQ:086890) Takes On Some Risk With Its Use Of Debt

Jun 10
ISU Abxis (KOSDAQ:086890) Takes On Some Risk With Its Use Of Debt

Recent updates

ISU Abxis Co., Ltd.'s (KOSDAQ:086890) Intrinsic Value Is Potentially 84% Above Its Share Price

Aug 07
ISU Abxis Co., Ltd.'s (KOSDAQ:086890) Intrinsic Value Is Potentially 84% Above Its Share Price

ISU Abxis (KOSDAQ:086890) Takes On Some Risk With Its Use Of Debt

Jun 10
ISU Abxis (KOSDAQ:086890) Takes On Some Risk With Its Use Of Debt

Benign Growth For ISU Abxis Co., Ltd. (KOSDAQ:086890) Underpins Its Share Price

Mar 12
Benign Growth For ISU Abxis Co., Ltd. (KOSDAQ:086890) Underpins Its Share Price

We Think ISU Abxis (KOSDAQ:086890) Has A Fair Chunk Of Debt

Feb 17
We Think ISU Abxis (KOSDAQ:086890) Has A Fair Chunk Of Debt

ISU Abxis'(KOSDAQ:086890) Share Price Is Down 21% Over The Past Three Years.

Dec 25
ISU Abxis'(KOSDAQ:086890) Share Price Is Down 21% Over The Past Three Years.

Shareholder Returns

A086890KR BiotechsKR Market
7D-5.6%-2.5%-1.2%
1Y-1.8%40.2%4.8%

Return vs Industry: A086890 underperformed the KR Biotechs industry which returned 44.3% over the past year.

Return vs Market: A086890 underperformed the KR Market which returned 7.2% over the past year.

Price Volatility

Is A086890's price volatile compared to industry and market?
A086890 volatility
A086890 Average Weekly Movement5.9%
Biotechs Industry Average Movement9.6%
Market Average Movement6.7%
10% most volatile stocks in KR Market12.3%
10% least volatile stocks in KR Market3.6%

Stable Share Price: A086890 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A086890's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aYeob Hwangwww.abxis.com

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications; Febulein, a sodium phenylbutyrate granule for the treatment of urea dystrophy; and Trientop, a trientine hydrochloride capsule for the treatment of Wilson’s disease. It develops ISU104 for head, neck, colorectal, and breast cancer; ISU104 CAR-NK for leukemia and solid tumors; ABX2001 for solid tumors; ISU304 for hemophilia B; ISU305 for paroxysmal nocturnal hemoglobinuria and other autoimmune diseases; and ISU203 for dementia caused by Alzheimer’s disease.

ISU Abxis Co., Ltd. Fundamentals Summary

How do ISU Abxis's earnings and revenue compare to its market cap?
A086890 fundamental statistics
Market cap₩212.90b
Earnings (TTM)-₩5.97b
Revenue (TTM)₩62.05b

3.4x

P/S Ratio

-35.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A086890 income statement (TTM)
Revenue₩62.05b
Cost of Revenue₩17.52b
Gross Profit₩44.53b
Other Expenses₩50.50b
Earnings-₩5.97b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-166.28
Gross Margin71.76%
Net Profit Margin-9.62%
Debt/Equity Ratio38.3%

How did A086890 perform over the long term?

See historical performance and comparison